Ieramilimab, an IgG4 mAb anti-LAG-3, has been evaluated in combination with spartalizumab (mAb anti-PD-1) in a phase II study enrolled patients with different tumor types including SCLC relapsed or refractory to standard therapies. Here, LAG3 is linked to neoplasm.